Biotech Values

[iwfal]

The placebo arm , being frozen Provenge ( for crossovers ) , was not a 'true' placebo in these trials and confounds the results in a way that should incentivize the FDA to discourage this type of trial design in the future.

The FDA has a long history of allowing x-over in a trial with a surrogate endpoint after each patient has met the surrogate. This is not much different. So I don't understand your point.